LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aandelen Lijst・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Gesloten

SectorGezondheidszorg

1.87 -7.88

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.87

Max

1.92

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.8M -43M
EPS	-0.18
Werknemers	150
EBITDA	-3.9M -43M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+363.3% upside

Dividenden
By Dow Jones
Volgende Winsten	12 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-45M 742M
Vorige openingsprijs	9.75
Vorige sluitingsprijs	1.87

Nieuwssentiment

By Acuity

34%

66%

76 / 344 Rangschikking in Healthcare

Allogene Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jun 2026, 19:20 UTC

Belangrijke Marktbewegers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

7 jun 2026, 23:46 UTC

Marktinformatie

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

7 jun 2026, 23:36 UTC

Marktinformatie

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

7 jun 2026, 18:00 UTC

Winsten

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

6 jun 2026, 12:40 UTC

Acquisities, Fusies, Overnames

Correction to Texas Billionaires Article America's Resort -- WSJ

6 jun 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

6 jun 2026, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

6 jun 2026, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 jun 2026, 00:14 UTC

Acquisities, Fusies, Overnames

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 jun 2026, 21:27 UTC

Winsten

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Marktinformatie

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Marktinformatie

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Marktinformatie

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Marktinformatie

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Marktinformatie

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Acquisities, Fusies, Overnames

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Winsten

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Marktinformatie

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Allogene Therapeutics Inc Prognose

Koersdoel

By TipRanks

363.3% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 8.71 USD 363.3%

Hoogste 14 USD

Laagste 3.85 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Allogene Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Gebaseerd op 14 analisten die aandelenratings hebben gegeven aan Allogene Therapeutics Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

76 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.